Rather than acting solely through weight loss or peripheral glucose control, GLP-1 therapies engage neural pathways involved in energy regulation, inflammation, synaptic integrity, and protein homeostasisoffering a biologically coherent explanation for their emerging association with preserved cognitive function and reduced dementia risk
The FDA has documented fraudulent compounded semaglutide and tirzepatide products carrying false label information, including labels naming compounding pharmacies that do not exist and labels naming licensed pharmacies that did not compound the product
For the person with severe needle phobia who would otherwise forgo GLP-1 therapy entirely, drops offer a meaningful, if imperfect, alternative
#BusinessOfDrinks #GLP1 #DrinksIndustry #ConsumerTrends #RetailInsights #WineAndSpirits #AdultBeverage Scott Rosenbaum Caroline Lamb Watch on YouTube: Great interview and such an interesting subject
A rare complication of this deficiency is optic neuropathy which results in progressive, bilateral, painless vision loss
